KeyBanc Initiates MAXIMUS Shares With Overweight Rating, $63 Target

MAXIMUS, Inc. MMS shares traded up nearly 5 percent Thursday following a new Overweight and $63 price target from KeyBanc analyst Jason Twizell.

"We believe MMS can realize upside to consensus EPS estimates given continued growth in the outsourcing of government health programs, including new U.S.specific Medicaid and Health Insurance Exchange opportunities, along with margin maturation for its newer contracts," Twizell said.

The KeyBanc analyst highlighted the possibility for MAXIMUS to benefit from government-sponsored healthcare programs which continue to transition this kind of management to the private sector. "We believe Medicaid and health insurance exchange-based enrollment growth will provide MMS new and expanded contract opportunities around eligibility, enrollment, provider credentialing, and health assessments," according to Twizell.

As MAXIMUS shares closed Thursday's session at $55.37, Twizell's new price target represented potential upside of about 14 percent.